Study: FDA offers flexibility, expedited review to first-in-class drugs more often than EMA
Regulatory NewsJeff Craven
Approval/marketing authorizationBiologics/ biosimilars/ vaccinesEuropeExpedited pathwaysPharmaceuticalsProduct LifecycleSubmission and registrationUnited States